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Universite´ Paris Sud 11, Le Kremlin Biceˆtre, FranceRecent studies have uncovered profound and unexpected roles for a family of tiny regulatory RNAs, known as microR-
NAs (miRNAs), in the control of diverse aspects of hepatic function and dysfunction, including hepatocyte growth, stress
response, metabolism, viral infection and proliferation, gene expression, and maintenance of hepatic phenotype. In liver
cancer, misexpression of speciﬁc miRNAs suggests diagnostic and prognostic signiﬁcance. Here, we review the biology
of the most abundant miRNA in human liver, miR-122, and consider the diversity of its roles in the liver. We provide a
compilation of all miRNAs expressed in the liver, and consider some possible therapeutic opportunities for exploiting miR-
NAs in the diﬀerent settings of liver diseases.
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The RNA interference (RNAi) pathway achieves
silencing of gene expression. The best characterized trig-
gers of RNAi are small interfering RNAs (siRNAs) and
endogenous double-stranded (ds) RNAs. The predomi-
nant form of dsRNA in mammalian cells is derived from
endogenous microRNAs (miRNAs), which consist of
non-coding RNA molecules of 18–25 nucleotides emerg-
ing after a multiple step maturation process [1].0168-8278/$34.00  2008 European Association for the Study of the Liver.
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induced silencing complex.First discovered in Caenorhabditis elegans [2], miR-
NAs have quickly been considered as a fundamental com-
ponent of the regulatory system of gene expression.
miRNAs direct the binding of protein complexes to spe-
ciﬁc nucleic acid sequences to aﬀect either chromatin
structure, or mRNA stability, or translation. In humans,
the ﬁrst clue of miRNA contributing to diseases came
from the identiﬁcation of patients suﬀering from either
DiGeorge syndrome ormental retardationwho presented
mutations, which resulted in dysfunction of miRNA bio-
genesis [3]. So far,most eﬀorts have been directed towards
the study of alteration of miRNA expression in tumori-
genesis [3]. Today, approximately 500 miRNAs genes
have been identiﬁed in the human genome.
Currently, the biological functions of miRNAs are
actively being sought. Some studies have notably uncov-
ered roles formiRNAs in stress resistance, inmetabolism,
in defence against pathogenic infections, and impor-
tantly, in the coordination of cell proliferation and cell
death, in tumorigenesis. How a single miRNA regulates
multiple-targetmRNAs or even entire pathways is partic-Published by Elsevier B.V. All rights reserved.
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122. Thus, miR-122 accounts for a paradigm to review
most of the complex inﬂuences of microRNAs reported
to date in normal liver, and in liver diseases along with
their therapeutic or diagnostic potential.2. miR-122: a liver-speciﬁc microRNA
2.1. Discovery and biogenesis of miR-122
One of the ﬁrst clues of the existence of miRNAs in
mammals came from studies on genetic alterations in
woodchuck liver tumors. In 1989, a gene rearrangement
of c-myc and an unusual transcript, named hcr, was
described in one of these tumors [4]. This transcript
was characterized as liver speciﬁc, essentially non-cod-
ing, speciﬁcally nuclear, and processed by endonucleases
[4]. Further, hcr was proposed to be the precursor for
miR-122. In the current understanding, the part of the
hcr transcript encompassing the so-called ‘‘pri-miRNA”
is predicted to be processed to form a 66-nt long ‘‘pre-
miRNA”, which presents a hairpin structure with 79%
base pairing, and which will ultimately be cleaved by
the endonuclease Dicer to form the mature miR-122 [5].
In 2002, systematic cloning and sequencing of small
RNAs prepared from diﬀerent mouse tissues led to the
identiﬁcation of miR-122 as an abundant miRNA in
the liver [6]. miR-122 was further characterized as the
most frequent miRNA isolated in the adult liver, reach-
ing around 70% of all cloned miRNAs [7]. miR-122 is
found in mouse, woodchuck and human livers, in
human primary hepatocytes, and in cultured liver-
derived cells, such as mouse Hepa 1-6 cells and human
Huh7 cells [5,8].Fig. 1. Phylogenetic tree of miR-122 sequences. For analysis, we selected 1
accession numbers are indicated for each sequence. The phylogenetic tree is b
method. Distance scale is shown below. Full species names corresponding to t
musculus; hsa, Homo sapiens; gga, Gallus gallus; mdo, Monodelphis domestica
rno, Rattus novergicus; dre, Danio rerio. Despite the short sequences, the maj
vertebrates cluster well in the upper part of the tree.2.2. Evolutionary conservation of miR-122
MicroRNAs are known to be evolutionary conserved
across species [9]. Here, we examined genomic DNA for
orthologous sequences in ten animal species to assess the
conservation of miR-122 across species. The overall con-
servation of 10 sequences, which we documented as a
phylogenetic tree (Fig. 1) is remarkable. Homo sapiens,
Bos Taurus, Sus scrofa, Mus musculus, and Rattus nor-
vegicus are clustered in the same clade. These observa-
tions support the hypothesis that an ancient precursor
of the miR-122 gene may have been common to the ear-
liest animal lineages. So far, the role and speciﬁcity of
miR-122 in the liver seem rather conserved although it
is known that a conserved miRNA can regulate, in dis-
tinct organisms, diﬀerent genetic pathways and develop-
mental processes [10].
2.3. miR-122 amongst other liver-expressed miRNAs
A variety of experimental approaches has been used to
characterize miRNAs and their expression patterns
[6,11–14]. Complementary bioinformatics screens and
algorithms provide an invaluable source of prediction of
hundreds of additional miRNAs [15–17]. A review of
the literature reveals limited references in the identiﬁca-
tion of miRNAs that are speciﬁcally expressed in
human liver [18–21]. We compiled these miRNAs and
their relative levels of expression in Table 1. From
this table, overall comparison between the miRNAs that
are expressed in adult and/or fetal liver suggests a
developmental regulation of miRNAs expression. While
miR-122 appears as the most highly expressed miRNA
in adult liver, miR-92a andmiR-483 seem to bemore spe-
ciﬁcally expressed in the fetal liver (Table 1). Thus, in the0 representative miR-122 RNA precursors amongst 10 species. Sanger
ased on a multi-gene analysis using MEGA v4.0 with Neighbor-Joining
he miRNAs are as follows: ssc, Sus scrofa; bta, Bos taurus; mmu, Mus
; tni, Tetraodon nigroviridis; fru, Fugu rubripes; xtr, Xenopus tropicalis;
or clades are well separated in this phylogenetic tree. Most mammalian
Table 1
Repertoire of liver miRNAs
Table 1 (continued)
Notes: The left column corresponds to the most up-to-date compila-
tion in the liver referred to as ‘‘atlas liver” [21], the middle column to
‘‘adult liver” [20], and the right column to ‘‘fetal liver” [19]. We
assigned ‘‘+” and ‘‘”signs to indicate the levels of expression of the
various miRNAs that we assessed from the diﬀerent studies [19,20].
The minus sign is used to indicate very low to undetectable levels, one
plus to three pluses indicate a gradual expression from low levels to
very high levels. The slash stands for the miRNAs that were not
assayed. Cases outlined in dark grey illustrate the highest levels of
expression and cases in light grey the moderate expression but found at
least in two studies.Abbreviation: hsa-miR: homo sapiens microRNA.
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liver diseases, miR-122 serves as an interesting candidate.3. Putative to experimentally validated targets of miR-122
3.1. Contribution of miR-122 in cellular stress response
Using computational tools, some genes, which were
proposed as putative miR-122-target genes, were further
experimentally conﬁrmed in cultured hepatocytes. Chang
et al. used theLewis-basedmodel of prediction ofmiRNA
targets [22] to predict a binding site for miR-122 in the
30-untranslated region (UTR) of the cationic amino acid
transporter (CAT-1) mRNA [7]. Consistent with this pre-
diction, which would lead to repression of CAT-1mRNA
by miR-122, an inversed pattern of expression of CAT-1
M. Girard et al. / Journal of Hepatology 48 (2008) 648–656 651andmiR-122 was noted at all stages of liver development.
An antisense strategy targeting miR-122 with a 20-O-
methoxyethyl (20-OMe) oligonucleotide in the human
Huh7 cells brought up the dynamic evidence that miR-
122 inhibited CAT-1 mRNA [23]. Interestingly, miR-
122-induced inhibition through the CAT-1 30UTR was
eﬃciently relieved upon amino acid starvation, which val-
idates CAT-1 as a target of miR-122 and suggests a role
for miR-122 in cellular stress response [23].
3.2. Contribution of miR-122 to hepatocarcinogenesis
miR-122 was reported to be signiﬁcantly and speciﬁ-
cally down-regulated in hepatocarcinoma (HCC) in
humans as in rodents [24,25]. Amongst the putative tar-
get genes of miR-122 that can be predicted using compu-
tational tools, at least three are of interest in
tumorigenesis: the gene for N-Myc, which is frequently











Fig. 2. Complexity of miRNA-mediated host–pathogen interaction. Genes wi
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lated in liver malignancy” [27], and the gene for Cyclin
G1 [28]. In fact, miR-122 was shown to modulate cyclin
G1 expression in HCC-derived cell lines, and an inverse
correlation between miR-122a and cyclin G1 expression
in primary liver carcinomas was further observed [28].
These studies suggest an inﬂuence of the down-regula-
tion of miR-122 and the converse expression of cyclin
G1 in hepatocarcinogenesis.
3.3. miR-122 targets hepatitis C virus
A striking observation was made by Jopling et al.
that replication of the hepatitis C virus (HCV) was
dependent on the status of miR-122 expression. Indeed,
HCV RNA can replicate in the Huh 7 cells, which
express miR-122, but not in HepG2 cells, which do
not express miR-122 [8]. To further assess the role of




















thin the host genome as well as the viral genome encode miRNAs and
ost miRNA in their regulation of either cellular (arrow 1) or viral mRNAs
mRNAs (arrow 3). In turn, four situations arise in which host-encoded
rotective enzyme heme-oxygenase 1 [29]), or virus-encoded miRNAs may
cl-2 mRNA [40]), or virus-encoded miRNAs may bind to viral mRNAs
r host-encoded miRNAs can target viral mRNAs (referred to as 4, e.g.,
.
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[29]. Using distinct antisense strategies, these studies
consistently resulted in a marked loss of replicating
RNAs from HCV [8] and eventually lowered its produc-
tion [29,30]. Mutational analysis of a putative miR-122
binding site in the 50-end of HCV genome provided
the evidence of the direct role of miR-122 into HCV rep-
lication [8]. Additionally, an indirect eﬀect of miR-122
inhibition on HCV regulation was also characterized
at the level of two cellular genes (Fig. 2), via the up-reg-
ulation of the cytoprotective enzyme heme-oxygenase 1
(HO-1) and the converse down-regulation of HO-1
repressor Bach1 [25]. Altogether, these studies reveal
miR-122 as a potential target for HCV treatment.
3.4. Overall role of miR-122 in adult liver
Using distinct protocols to silencemiR-122,Krutzfeldt
et al. andEsau et al. found the overall importance ofmiR-
122 in the regulation of metabolism [31,32]. Through an
antisense strategy based on a 20-OMe phosphorothio-
ate-modiﬁed oligonucleotide speciﬁc to miR-122, Esau
et al. observed that several genes that regulate lipidmetab-
olism, speciﬁcally the key enzyme phosphomevalonate
kinase, were down-regulated [32]. Remarkably, silencing
miR-122 in high-fat fed mice resulted in a signiﬁcant
reduction of hepatic steatosis, which was associated with
reduced cholesterol synthesis rates and stimulation of
hepatic fatty-acid oxidation [32].
Likewise, Krutzfeldt et al. proposed a novel antisense
strategy based on a cholesterol-conjugated 20-OMe
oligoribonucleotide complementary to the targeted
miR-122, and referred to it as an ‘‘antagomir” [31]. Silenc-
ing of the miR-122 resulted in increased expression of
several hundred genes, which were notably represented
as putative miR-122 target mRNAs, including those that
are normally repressed in hepatocytes. These results argue
for the involvement of miR-122 in maintaining an
adult-liver phenotype by suppressing the expression of
non-liver genes. At last, in both studies, silencing
miR-122 resulted in a notable decrease of plasma choles-
terol levels, which was consistently associated with
decreased expression of genes involved in cholesterol
biosynthesis. These results provided a great source of
hope thatmiRNAs could serve as therapeutic targets [33].4. Existing rationale for miR-based therapeutic
approaches
4.1. miR-122 antagomir as a new agent for liver-speciﬁc
RNAi
Antisense oligonucleotide approaches and siRNA-
like technologies for inhibiting miRNA function are
being explored as potential therapeutic agents. The cur-rent strategy to constitutively synthesize siRNA mole-
cules is based on viral vectors that express short
hairpin RNA (shRNA), which share features of miR-
NAs [34–36]. A particular caveat of this approach lies
in the dosage. Indeed, intravenous infusion of AAV/
shRNA vectors in mice results in strong competition
of small RNAs for limiting cellular factors required
for their processing [35], and a possible side eﬀect in
the activation of interferon response though no change
was noted in the expression of miR-122 [37].
Actually, the exciting ﬁrst step towards miRNA ther-
apy in the liver was with miR-122 antagomir [31]. In this
study, the pharmacological approach proposed by
Krutzfeldt et al. was remarkably eﬃcient, speciﬁc and
stable. Injection of the antagomir into the tail veins of
the mice selectively degraded miR-122 but not other
miRNAs from the liver, even after more than 20 days
indicating a durable eﬀect [31]. Also, the selectivity of
the eﬀect of miR-122 inhibition was provided by the fact
that despite distinct antisense protocols, a similar eﬀect
on cholesterol rates was observed [31,32]. Thus, in con-
trast to the challenges raised by gene therapy, the eﬃ-
cacy of intravenous antagomir to target the liver
suggests that some issues such as the mode of delivery
and the speciﬁcity will be more easily alleviated. Taken
together, these studies show that while some safety
issues still need to be carefully addressed, treatment of
hepatic disorders through RNAi is becoming a plausible
scenario.
4.2. Hepatitis viruses as adequate targets
Over the past 4 years, strategies based on targeting
hepatitis B virus (HBV), and to a lesser extent HCV,
by both synthetic and expressed activators of the RNAi
pathway have proved eﬃcient to inhibit viral replication
both in vitro as in vivo [38]. Recently, a number of
reports shed new light on the role of miRNAs as critical
eﬀectors in the intricate host–pathogen interaction net-
works, which involves three levels: (i) the RNAi path-
way, (ii) viral miRNAs, and (iii) cellular miRNAs, as
schematized in Fig. 2 and summarized in Table 2.
Through a systematic approach of silencing host fac-
tors, Randall et al. demonstrated the requirement of dif-
ferent proteins of the RNAi pathway, in particular
Dicer, for optimal HCV replication [30]. In contrast, a
previous study revealed the ability of Dicer to inhibit
the replication of subgenomic HCV replicons [39].
Together, these results indicate that Dicer interferes with
HCV replication either as an antiviral or a facilitating
factor, which then likely implicates other cellular
factors.
One breakthrough came from the discovery that a
number of viruses, including hepatotropic ones, encode
miRNAs. The ﬁrst evidence of viral miRNA (vmiRNA)
came from a study by Pfeﬀer et al. [40], who discovered
Table 2
Experimental characterization of miRNAs in the liver
Characterization miRNA References
Metabolism Regulation of lipid metabolism (cholesterol biosynthesis) miR-122 [31,32]
Maintenance of adult liver phenotype
Stress Inversed pattern expression miR-122/CAT-1 in liver miR-122 [23,59]
Alteration of cellular miRNA in response to nutrient or toxic stress
response
Response to hepatotoxicants miR-298, miR-370 [60]
Cancer Regulation of NF2, modulation by Stat-3 let-7a [54]
Involved in survival signaling by interleukin-6
Regulation of c-myc, regulated by Wy-14,643 let-7c Review [52]




Overexpression in HCC, modulation of cell proliferation LIN28B [51]
Overexpression in HCC, modulation of cell proliferation, migration and
invasion
miR-21 [25]
Overexpression in malignant cholangiocytes
Response of cholangiocarcinoma cells to chemotherapy miR-21 [47]
Epigenetic regulation by interleukin-6 miR-370 [61]
Inverse correlation with cyclin G1 expression in primary liver carcinoma miR-122 [28]
Regulation of cyclin G1 in HCC-derived cell lines
Low expression in HCC
High expression in response to tamoxifen and methyl-deﬁcient diet miR-34 [62,24]
Infection Viral miRNA
Putative vmiRNA within HBV genome vmiR [43]
Cellular miRNA
Inhibition of HCV replication Dicer [39]
Permissive of HCV replication, cytoprotection through modulation of
heme-oxygenase 1
miR-122 [8,29,30]
Targeting viral genomes and induced by interferon beta miR-1, miR-30, miR-128, miR-
196, miR-296, miR-351, miR-
431, miR-448
[63]
Abbreviations: miRNA, microRNA; vmiR, viral microRNA.
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(EBV) that interfere with EBV latency and also with
host cell genes expression [40] (Fig. 2). Since, vmiRNAs
have been cloned in Kaposi’s sarcoma-associated her-
pesvirus (KSHV), human cytomegalovirus (HCMV),
mouse gammaherpesvirus 68 (MHV68), herpes simplex
virus 1 (HSV1), and simian viruses (SV40) [41]. By con-
trast, no vmiRNAs have been cloned in RNA viruses
such as hepatitis delta virus (HDV) [5], nor HCV, nor
human inmmunodeﬁciency virus 1 (HIV1) [42]. Beyond
the negative cloning data on HCV, the existence of
vmiRNAs is unlikely in most RNA viruses that are cyto-
plasmic-restricted due to the need for pre-miRNA to be
processed in the cytoplasm. Early on, it has been dem-
onstrated that HDV RNA is resistant to Dicer action
[5]. More recently, extensive searches on hepatitis
viruses led to scan a single putative vmiRNA within
HBV genome [43]. Surprisingly, the only potential target
of this miRNA was not found within the human genome
but within its own genome (Fig. 2). This interesting ﬁnd-
ing suggests a novel mechanism of vmiRNA action and
opens new means to target hepatitis viruses.Experimentally, the recent study by Pedersen et al.
provided great insights into validating sequence-pre-
dicted targets of cellular miRNAs within the HCV gen-
ome (Fig. 2). Using results of miRNA microarray
analysis in response to the current standard treatment
for chronic HCV infection, i.e., interferon, they could
demonstrate that cellular miRNAs, including miR-122,
were speciﬁcally regulated by interferon displayed anti-
viral activity against HCV. Thus, as discussed above,
miRNAs, whether cellular or viral, have emerged as
viral regulators of host and/or viral gene expression.
As a consequence, the range of interactions possible
through miRNA–mRNA crosstalk at the host–patho-
gen interface becomes considerable.
4.3. Interests converging on miRNAs in liver cancer
treatment
There are diﬀerent means by which miRNAs give rise
to strong interests in cancer (Table 1). One is the intrigu-
ing link between fragile sites and the genomic location of
miRNAs [44], exempliﬁed by miR-122 embedded in the
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regions often involved in HCC – either by deletion or
by viral insertion – tend to encompass miRNA-contain-
ing regions. In particular, the common deletion found in
13q31 in human colocalizes with the cluster miR-17-92,
which is rather referred to as an oncogene [45]. Likewise,
it was suggested that HBV integration nearby miR-200a,
at the fragile FRA1A site in the genome, could promote
HCC through silencing miR-200a expression, which is
known to be decreased in HCC [46]. Another observa-
tion concerns the integration of AAV in mice, which
was shown to be associated with HCC, and was repeat-
edly localized in the same 6-kb region of chromosome
12, which encompasses no fewer than 34 miRNAs [35].
Conversely, it was noted by Meng et al. that miR-141,
which showed strong overexpression in malignant cho-
langiocytes, was speciﬁcally localized in 12p, a region
of known chromosomal aberration in biliary tract can-
cers [47].
Another reason for interest in miRNAs in cancer lies
in their putative role as master regulators of cellular pro-
cesses involved in tumorigenesis [48–50]. Speciﬁcally in
the liver, few miRNAs have been shown to modulate
important targets of proliferation such as miR-122
targeting cyclin G1, let-7 targeting LIN28B [51] and
c-myc in response to PPARalpha [52], or miR-141 target-
ing CLOCK, which can act as a tumor-suppressor [47].
Importantly, as demonstrated byMeng et al. miR-21 tar-
gets PTEN [47], and results in furthermodulation ofHCC
cell migration and invasion, through modulating the
phosphorylation of focal adhesion kinase and expression
ofmatrixmetalloproteinases 2 and 9 [25]. These data raise
further the potential interest in decreasingmiR-21 to limit
HCC growth and metastasis.
The important breakthrough in the ﬁeld of hepato-
carcinogenesis came from the accurate correlation of
alterations in miRNAs with tumor proliferation and dif-
ferentiation. Notably in HCC, this alteration seems to
take place at the expression level rather than at the
sequence levels [53]. So far, there has been very limited
insight into the characterization of this modulation,
though the inﬂuence of interleukin-6 in malignant cho-
langiocytes was noted [54]. Using miRNA microarray
analysis in patient-derived paired samples from the
tumoral tissue and the non-tumoral adjacent tissues,
Murakami et al. [55] found miR-92, miR-20, miR-18,
and miR-18 precursor, which were inversely correlated
with the degree of HCC diﬀerentiation. Consistent with
diﬀerent studies, miR-199a and miR-21 were, respec-
tively, found lowered and overexpressed [24,25,28,55].
Therefore, it appears that a limited number of miRNAs,
which could stand as an miRNA signature, could help in
future molecular proﬁling of HCC [55,56]. These obser-
vations in HCC are all the more interesting because
diagnostic and prognostic signiﬁcance of any tested
markers has proved limited due to their high variability.Furthermore, Meng et al. showed that inhibition of
miR-21 sensitized the response of cholangiocarcinoma
cell lines to chemotherapy [47]. This observation gives
rise to signiﬁcant hope that miR-21 could serve as a bio-
marker for drug response in cholangicarcinoma.
4.4. Therapeutic opportunities and challenges
In the near future, the distinctive signature patterns
of miRNA expression associated with liver cancer
should allow classiﬁcation of diﬀerent stages in tumor
progression. Further, creating artiﬁcial miRNAs with
salutary eﬀects by promoting the expression of beneﬁcial
gene products (e.g., tumor-suppressor proteins) or tar-
geting viral genomes (e.g., molecules designed to specif-
ically target HCV-genome sequences) may become part
of our patient management and complement chemother-
apy and antiviral treatments.
As for miR-122, its role in regulating cholesterol bio-
synthesis, in maintaining the adult-liver phenotype, its
association with hepatocarcinogenesis and its role in
HCV replication make it an invaluable target to expand
our knowledge in the pathophysiology of diverse liver
diseases. One potential therapeutic application comes
from the eﬀect of miR-122 antagomir in high-fat fed
mice to reduce hepatic steatosis [31], which may provide
an interesting opportunity to treat patients with non-
alcoholic steatohepatitis. Another interesting applica-
tion of miR-122 antagomir consists in taking advantage
of its eﬀect on the down-regulation of adult-liver genes
expression [31] to generate in vitro a new attractive
expandable cell source for hepatocyte transplantation
that would feature stem/progenitor cell phenotype.
It has been less than 5 years since the discovery that
natural miRNAs were also functional in humans [57].
So far, the fast pace of discovery in this ﬁeld is providing
increasing rationale for manipulating miRNAs thera-
peutically. As such the number of recent patent applica-
tions is growing quickly [58]. Given the broad eﬀects of
miR-122 in the liver, and the number of miRNAs, it is
quite certain that many new and unanticipated roles of
miRNAs in the control of normal and abnormal liver
function are awaiting discovery.
References
[1] Ambros V. The functions of animal microRNAs. Nature
2004;431:350–355.
[2] Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D.
MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr
Biol 2003;13:807–818.
[3] Chang TC, Mendell JT. The roles of microRNAs in vertebrate
physiology and human disease. Annu Rev Genomics Hum Genet
2007;8:215–239.
[4] Moroy T, Etiemble J, Bougueleret L, Hadchouel M, Tiollais P,
Buendia MA. Structure and expression of hcr, a locus rearranged
with c-myc in a woodchuck hepatocellular carcinoma. Oncogene
1989;4:59–65.
M. Girard et al. / Journal of Hepatology 48 (2008) 648–656 655[5] Chang J, Provost P, Taylor JM. Resistance of human hepatitis
delta virus RNAs to Dicer activity. J Virol 2003;77:11910–11917.
[6] Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W,
Tuschl T. Identiﬁcation of tissue-speciﬁc microRNAs from
mouse. Curr Biol 2002;12:735–739.
[7] Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA,
et al. miR-122, a mammalian liver-speciﬁc microRNA, is pro-
cessed from hcr mRNA and may downregulate the high aﬃnity
cationic amino acid transporter CAT-1. RNA Biol
2004;1:106–113.
[8] Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P.
Modulation of hepatitis C virus RNA abundance by a liver-
speciﬁc MicroRNA. Science 2005;309:1577–1581.
[9] Bartel DP, Chen CZ. Micromanagers of gene expression: the
potentially widespread inﬂuence of metazoan microRNAs. Nat
Rev Genet 2004;5:396–400.
[10] Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda
MI, Maller B, et al. Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature
2000;408:86–89.
[11] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identi-
ﬁcation of novel genes coding for small expressed RNAs. Science
2001;294:853–858.
[12] Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T.
New microRNAs from mouse and human. Rna 2003;9:175–179.
[13] Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of
tiny RNAs with probable regulatory roles in Caenorhabditis
elegans. Science 2001;294:858–862.
[14] Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT,
et al. Real-time quantiﬁcation of microRNAs by stem-loop RT-
PCR. Nucleic Acids Res 2005;33:e179.
[15] Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O,
et al. Identiﬁcation of hundreds of conserved and nonconserved
human microRNAs. Nat Genet 2005;37:766–770.
[16] Berezikov E, Plasterk RH. Camels and zebraﬁsh, viruses and
cancer: a microRNA update. Hum Mol Genet
2005;14:R183–R190.
[17] Hammond SM. MicroRNA therapeutics: a new niche for
antisense nucleic acids. Trends Mol Med 2006;12:99–101.
[18] Sempere SM, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky
E, Ambros V. Expression proﬁling of mammalian microRNAs
uncovers a subset of brain-expressed microRNAs with possible
roles in murine and human neuronal diﬀerentiation. Genome Biol
2004;5:R13.
[19] Fu H, Tie Y, Xu C, Zhang Z, Zhu J, Shi Y, et al. Identiﬁcation of
human fetal liver miRNAs by a novel method. FEBS Lett
2005;579:3849–3854.
[20] Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I,
et al. MicroRNA expression detected by oligonucleotide micro-
arrays: system establishment and expression proﬁling in human
tissues. Genome Res 2004;14:2486–2494.
[21] Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A,
et al. A mammalian microRNA expression atlas based on small
RNA library sequencing. Cell 2007;129:1401–1414.
[22] Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB.
Prediction of mammalian microRNA targets. Cell
2003;115:787–798.
[23] Bhattacharyya SN, Habermacher R, Martine U, Closs EI,
Filipowicz W. Relief of microRNA-mediated translational repres-
sion in human cells subjected to stress. Cell 2006;125:1111–1124.
[24] Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W,
et al. Downregulation of miR-122 in the rodent and human
hepatocellular carcinomas. J Cell Biochem 2006;99:671–678.
[25] Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel
T. MicroRNA-21 regulates expression of the PTEN tumor
suppressor gene in human hepatocellular cancer. Gastroenterol-
ogy 2007;133:647–658.[26] Jacob JR, Sterczer A, Toshkov IA, Yeager AE, Korba BE, Cote
PJ, et al. Integration of woodchuck hepatitis and N-myc
rearrangement determine size and histologic grade of hepatic
tumors. Hepatology 2004;39:1008–1016.
[27] Harada H, Nagai H, Ezura Y, Yokota T, Ohsawa I, Yamaguchi
K, et al. Down-regulation of a novel gene, DRLM, in human liver
malignancy from 4q22 that encodes a NAP-like protein. Gene
2002;296:171–177.
[28] Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S,
Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA
frequently down-regulated in human hepatocellular carcinoma.
Cancer Res 2007;67:6092–6099.
[29] Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal
eﬀects of micro-RNA-122 on expression of heme oxygenase-1 and
hepatitis C virus genes in human hepatocytes. Gastroenterology
2007;133:1166–1174.
[30] Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets
KE, Pfeﬀer S, et al. Cellular cofactors aﬀecting hepatitis C virus
infection and replication. Proc Natl Acad Sci USA
2007;104:12884–12889.
[31] Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T,
Manoharan M, et al. Silencing of microRNAs in vivo with
‘antagomirs’. Nature 2005;438:685–689.
[32] Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al.
miR-122 regulation of lipid metabolism revealed by in vivo
antisense targeting. Cell Metab 2006;3:87–98.
[33] Czech MP. MicroRNAs as therapeutic targets. N Engl J Med
2006;354:1194–1195.
[34] Carmona S, Ely A, Crowther C, Moolla N, Salazar FH, Marion
PL, et al. Eﬀective inhibition of HBV replication in vivo by anti-
HBx short hairpin RNAs. Mol Ther 2006;13:411–421.
[35] Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis
CR, et al. Fatality in mice due to oversaturation of cellular
microRNA/short hairpin RNA pathways. Nature
2006;441:537–541.
[36] Ying RS, Zhu C, Fan XG, Li N, Tian XF, Liu HB, et al. Hepatitis
B virus is inhibited by RNA interference in cell culture and in
mice. Antiviral Res 2007;73:24–30.
[37] Witting SR, Brown M, Saxena R, Nabinger S, Morral N. Helper-
dependent adenovirus-mediated shRNA expression in the liver
activates the interferon response. J Biol Chem
2008;283:2120–2128.
[38] Ying C, De Clercq E, Neyts J. Selective inhibition of hepatitis B
virus replication by RNA interference. Biochem Biophys Res
Commun 2003;309:482–484.
[39] Wang Y, Kato N, Jazag A, Dharel N, Otsuka M, Taniguchi H,
et al. Hepatitis C virus core protein is a potent inhibitor of RNA
silencing-based antiviral response. Gastroenterology
2006;130:883–892.
[40] Pfeﬀer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al.
Identiﬁcation of virus-encoded microRNAs. Science
2004;304:734–736.
[41] Pfeﬀer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene
2006;25:6211–6219.
[42] Pfeﬀer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C,
Grasser FA, et al. Identiﬁcation of microRNAs of the herpesvirus
family. Nat Methods 2005;2:269–276.
[43] Jin WB, Wu FL, Kong D, Guo AG. HBV-encoded microRNA
candidate and its target. Comput Biol Chem 2007;31:124–126.
[44] Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E,
Yendamuri S, et al. Human microRNA genes are frequently
located at fragile sites and genomic regions involved in cancers.
Proc Natl Acad Sci USA 2004;101:2999–3004.
[45] Lin YW, Sheu JC, Liu LY, Chen CH, Lee HS, Huang GT, et al.
Loss of heterozygosity at chromosome 13q in hepatocellular
carcinoma: identiﬁcation of three independent regions. Eur J
Cancer 1999;35:1730–1734.
656 M. Girard et al. / Journal of Hepatology 48 (2008) 648–656[46] Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites,
and hepatocarcinogenesis. Cancer Lett 2007;252:157–170.
[47] Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell
JT, et al. Involvement of human micro-RNA in growth and
response to chemotherapy in human cholangiocarcinoma cell
lines. Gastroenterology 2006;130:2113–2129.
[48] He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D,
Goodson S, et al. A microRNA polycistron as a potential human
oncogene. Nature 2005;435:828–833.
[49] O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-
Myc-regulated microRNAs modulate E2F1 expression. Nature
2005;435:839–843.
[50] Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F,
et al. A microRNA expression signature of human solid tumors
deﬁnes cancer gene targets. Proc Natl Acad Sci USA 2006;103:
2257–2261.
[51] Guo Y, Chen Y, Ito H, Watanabe A, Ge X, Kodama T, et al.
Identiﬁcation and characterization of lin-28 homolog B (LIN28B)
in human hepatocellular carcinoma. Gene 2006;384:51–61.
[52] Gonzalez FJ, Shah YM. PPARalpha: mechanism of species
diﬀerences and hepatocarcinogenesis of peroxisome proliferators.
Toxicology 2007, [Epub ahead of print].
[53] Yang J, Zhou F, Xu T, Deng H, Ge YY, Zhang C, et al. Analysis
of sequence variations in 59 microRNAs in hepatocellular
carcinomas. Mutat Res 2008;638:205–209.
[54] Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T.
The MicroRNA let-7a modulates interleukin-6-dependent STAT-
3 survival signaling in malignant human cholangiocytes. J Biol
Chem 2007;282:8256–8264.[55] Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H,
Okanoue T, et al. Comprehensive analysis of microRNA expres-
sion patterns in hepatocellular carcinoma and non-tumorous
tissues. Oncogene 2006;25:2537–2545.
[56] Roessler S, Budhu A, Wang XW. Future of molecular proﬁling
of human hepatocellular carcinoma. Future Oncol 2007;3:
429–439.
[57] Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro
RNAs can inhibit the expression of cognate mRNAs when
expressed in human cells. Mol Cell 2002;9:1327–1333.
[58] Recent patent applications in microRNAs. Nat Biotechnol
2006;24:44.
[59] Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular
stress. Cancer Res 2006;66:10843–10848.
[60] Fukushima T, Hamada Y, Yamada H, Horii I. Changes of micro-
RNA expression in rat liver treated by acetaminophen or carbon
tetrachloride–regulating role of micro-RNA for RNA expression.
J Toxicol Sci 2007;32:401–409.
[61] Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T.
Epigenetic regulation of microRNA-370 by interleukin-6
in malignant human cholangiocytes. Oncogene 2008;27:
378–386.
[62] Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R,
Beland FA, Kovalchuk O. Induction of microRNAome deregu-
lation in rat liver by long-term tamoxifen exposure. Mutat Res
2007;619:30–37.
[63] Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari
FV, et al. Interferon modulation of cellular microRNAs as an
antiviral mechanism. Nature 2007;449:919–922.
